Skip to main content
. 2023 Apr 3;80(4):114. doi: 10.1007/s00018-023-04765-0

Table 2.

Pharmacological data for tested compounds (antagonists retrieved within this study) and the reference agonists FFA and aristolochic acid obtained by measuring Gαqi-mediated accumulation of IPa1

Agonistic effect Inhibitory effectb
EC50 (µM)c Emax (%)d nf FFA as agonist Aristolochic acid as agonist
IC50 (µM)f Emax (%)g Ne IC50 (µM)h Emax (%)g Ne
FFA 0.43 ± 0.04 100 10
Aristol. acid 0.83 ± 0.2 100 4
LW 118 < 5 2 4.0 ± 0.49 83 ± 4 8 2.7 ± 4.1 82 ± 17 3
LW 129 < 5 3 3.7 ± 0.62 > 95 5
LW 131 < 5 2 4.1 ± 1.6 > 95 2
LW 145 3.2 ± 1.2 − 14 ± 5 6/11 3.8 ± 0.64 88 ± 6 5
LW 148 < 5 6 4.4 ± 1.6 > 95 6
LW 209 0.48 ± 0.1 − 19 ± 3 4 4.1 ± 1.3 96 ± 4 3
LWYW22 < 5 1 3.8 ± 1.5 > 95 2
LF1 − 8 2 6.8 ± 3.2 75 ± 7 5 11 ± 6.1 > 95 3
LF14 − 15 ± 22 2 22 ± 16 76 ± 17 3 14.3 ± 5.8 53 ± 10 3
LF22 − 29 ± 5.6 2 7.2 ± 3.7 63 ± 13 3 4.3 ± 2.6 59 ± 16 3

aMeasurement of G-protein signaling was performed applying the IP-One assay® (Cisbio) in HEK293T cells transiently co-transfected with the human TAS2R14 receptor and the hybrid G-protein Gαqi

bInhibition of the agonist effect of 1 µM of FFA/aristolochic acid

cPotency of TAS2R14 activation as mean value in µM ± SEM

dMaximum efficacy in % ± SEM relative to the full effect of FFA

eNumber of individual experiments all performed in duplicates/triplicates

fPotency to inhibit the effect of 1 µM FFA as mean value in µM ± SEM

gMaximum inhibitory efficacy was analyzed by subtracting the effect at the highest concentrations of test compound suitable for inhibition from 100% and is displayed as % ± SEM

hPotency to inhibit the effect of 1 µM aristolochic acid as mean value in µM ± SEM